Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Naltrexone / bupropion (Mysimba®) has been rejected for use as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of:

  • ≥ 30 kg/m² (obese), or
  • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)

The manufacturer failed to make a submission for this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2018' on Email Share 'SMC Update - May 2018' on Delicious Share 'SMC Update - May 2018' on Digg Share 'SMC Update - May 2018' on Facebook Share 'SMC Update - May 2018' on Google+ Share 'SMC Update - May 2018' on reddit Share 'SMC Update - May 2018' on StumbleUpon Share 'SMC Update - May 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,953 spam comments.

atomic-wealth
fond-illness
summer